Cargando…
An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration
Lecithin cholesterol acyltransferase (LCAT) plays a key role in the reverse cholesterol transport (RCT) process by converting cholesterol to cholesteryl ester to form mature HDL particles, which in turn deliver cholesterol back to the liver for excretion and catabolism. HDL levels in human plasma ar...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726446/ https://www.ncbi.nlm.nih.gov/pubmed/19680471 |
_version_ | 1782170604530565120 |
---|---|
author | Chen, Xun Burton, Charlotte Song, Xuelei Mcnamara, Lesley Langella, Annunziata Cianetti, Simona Chang, Ching H. Wang, Jun |
author_facet | Chen, Xun Burton, Charlotte Song, Xuelei Mcnamara, Lesley Langella, Annunziata Cianetti, Simona Chang, Ching H. Wang, Jun |
author_sort | Chen, Xun |
collection | PubMed |
description | Lecithin cholesterol acyltransferase (LCAT) plays a key role in the reverse cholesterol transport (RCT) process by converting cholesterol to cholesteryl ester to form mature HDL particles, which in turn deliver cholesterol back to the liver for excretion and catabolism. HDL levels in human plasma are negatively correlated with cardiovascular risk and HDL functions are believed to be more important in atheroprotection. This study investigates whether and how D-4F, an apolipoprotein A-I (apoA-I) mimetic peptide, influences LCAT activity in the completion of the RCT process. We demonstrated that the apparent rate constant value of the LCAT enzyme reaction gives a measure of LCAT activity and determined the effects of free metals and a reducing agent on LCAT activity, showing an inhibition hierarchy of Zn(2+)>Mg(2+)>Ca(2+) and no inhibition with β-mercaptoethanol up to 10 mM. We reconstituted nano-disc particles using apoA-I or D-4F with phospholipids. These particles elicited good activity in vitro in the stimulation of cholesterol efflux from macrophages through the ATP-binding cassette transporter A1 (ABCA1). With these particles we studied the LCAT activity and demonstrated that D-4F did not activate LCAT in vitro. Furthermore, we have done in vivo experiments with apoE-null mice and demonstrated that D-4F (20 mg/kg body weight, once daily subcutaneously) increased LCAT activity and HDL level as well as apoA-I concentration at 72 hours post initial dosing. Finally, we have established a correlation between HDL concentration and LCAT activity in the D-4F treated mice. |
format | Text |
id | pubmed-2726446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-27264462009-08-13 An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration Chen, Xun Burton, Charlotte Song, Xuelei Mcnamara, Lesley Langella, Annunziata Cianetti, Simona Chang, Ching H. Wang, Jun Int J Biol Sci Research Paper Lecithin cholesterol acyltransferase (LCAT) plays a key role in the reverse cholesterol transport (RCT) process by converting cholesterol to cholesteryl ester to form mature HDL particles, which in turn deliver cholesterol back to the liver for excretion and catabolism. HDL levels in human plasma are negatively correlated with cardiovascular risk and HDL functions are believed to be more important in atheroprotection. This study investigates whether and how D-4F, an apolipoprotein A-I (apoA-I) mimetic peptide, influences LCAT activity in the completion of the RCT process. We demonstrated that the apparent rate constant value of the LCAT enzyme reaction gives a measure of LCAT activity and determined the effects of free metals and a reducing agent on LCAT activity, showing an inhibition hierarchy of Zn(2+)>Mg(2+)>Ca(2+) and no inhibition with β-mercaptoethanol up to 10 mM. We reconstituted nano-disc particles using apoA-I or D-4F with phospholipids. These particles elicited good activity in vitro in the stimulation of cholesterol efflux from macrophages through the ATP-binding cassette transporter A1 (ABCA1). With these particles we studied the LCAT activity and demonstrated that D-4F did not activate LCAT in vitro. Furthermore, we have done in vivo experiments with apoE-null mice and demonstrated that D-4F (20 mg/kg body weight, once daily subcutaneously) increased LCAT activity and HDL level as well as apoA-I concentration at 72 hours post initial dosing. Finally, we have established a correlation between HDL concentration and LCAT activity in the D-4F treated mice. Ivyspring International Publisher 2009-07-28 /pmc/articles/PMC2726446/ /pubmed/19680471 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Research Paper Chen, Xun Burton, Charlotte Song, Xuelei Mcnamara, Lesley Langella, Annunziata Cianetti, Simona Chang, Ching H. Wang, Jun An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration |
title | An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration |
title_full | An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration |
title_fullStr | An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration |
title_full_unstemmed | An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration |
title_short | An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration |
title_sort | apoa-i mimetic peptide increases lcat activity in mice through increasing hdl concentration |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726446/ https://www.ncbi.nlm.nih.gov/pubmed/19680471 |
work_keys_str_mv | AT chenxun anapoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT burtoncharlotte anapoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT songxuelei anapoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT mcnamaralesley anapoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT langellaannunziata anapoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT cianettisimona anapoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT changchingh anapoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT wangjun anapoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT chenxun apoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT burtoncharlotte apoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT songxuelei apoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT mcnamaralesley apoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT langellaannunziata apoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT cianettisimona apoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT changchingh apoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration AT wangjun apoaimimeticpeptideincreaseslcatactivityinmicethroughincreasinghdlconcentration |